Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study

Table 1 Baseline characteristics of the cohort of 107 patients who started infliximab treatment

	Number of valid values	Baseline characteristics
Age (years), mean ± SD	104	41.8 ± 12.0
Disease duration (years)^†, mean ± SD male sex, n (%) HLA-B27 positive, n (%)	91,107 77	11.9 ± 10.4 75 (70.1%) 69 (89.6%)
Modified Schober test (cm), mean ± SD	87	3.7 ± 1.9
Fingertip to floor distance (cm), mean ± SD	101	19.6 ± 13.9
Number of swollen joints¸ mean ± SD	107	1.13 ± 2.2
CRP (mg/dl), mean ± SD	103	2.23 ± 2.82
ESR (mm/h), mean ± SD	105	35.3 ± 28.0
VAS nocturnal spinal pain (cm), mean ± SD	99	5.7 ± 2.8
VAS spinal pain(cm), mean ± SD	98	6.3 ± 2.4
VAS patient global (cm), mean ± SD	99	7.2 ± 1.8
BASDAI score (cm), mean ± SD	102	6.2 ± 1.9
BASFI score (cm)¸ mean ± SD	100	4.9 ± 2.7

n number, SD standard deviation, CRP C-reactive protein, ESR erythrocyte sedimentation rate, VAS patient’s rating of pain by visual analogue scale ranging from 0 (none) to 10 (worst), BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index
^†50% of patients had less than 10 years of disease duration

ISSN: 1478-6362